Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. News
  7. Summary
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Hyloris Pharmaceuticals Sa Launches Maxigesic IV

07/08/2021 | 01:00am EDT

Hyloris Pharmaceuticals SA announced that Maxigesic IV is now available in Germany and Austria. Maxigesic IV is a novel, patented, non-opioid treatment for post-operative pain and is a unique combination of 1000mg paracetamol and 300mg ibuprofen solution for infusion. Hyloris’ partner AFT Pharmaceuticals works together with distribution partners with strong local presence to commercialise the product globally. Maxigesic IV is currently licensed in more than 100 countries across the globe, and it has been registered in 24 countries. Following the launch in Germany and Austria, the product is now available in 5 countries: Australia, New Zealand, The United Arab Emirates, Germany, and Austria.


ę S&P Capital IQ 2021
All news about HYLORIS PHARMACEUTICALS SA
09/23HYLORIS PHARMACEUTICALS : Appoints New CFO From Bone Therapeutics
MT
09/23HYLORIS PHARMACEUTICALS : Appoints Jean-Luc Vandebroek as Chief Financial Officer
AQ
09/23Hyloris Pharmaceuticals SA Appoints Jean-Luc Vandebroek as its Chief Financial Officer
CI
09/21HYLORIS PHARMACEUTICALS' : Post-Operative Pain Drug Wins OK in South Korea, Panama
MT
09/21HYLORIS PHARMACEUTICALS : Announces Further Extension of Maxigesic« IV Footprint
AQ
09/21Hyloris Pharmaceuticals SA Announces Further Extension of Maxigesic« Iv Footprint
CI
08/04Hyloris Pharmaceuticals Sa Reports Earnings Results for the Second Quarter Ended June 3..
CI
08/04Hyloris Pharmaceuticals SA Reports Consolidated Earnings Results for the Half Year Ende..
CI
07/27HYLORIS PHARMACEUTICALS : to Report 2021 Half-Year Results on 4 August 2021
AQ
07/08HYLORIS PHARMACEUTICALS : Starts Selling Non-Opioid Painkiller in Germany, Austria
MT
More news
Financials
Sales 2020 0,95 M 1,11 M 1,11 M
Net income 2020 -6,00 M -7,03 M -7,03 M
Net cash 2020 48,0 M 56,2 M 56,2 M
P/E ratio 2020 -8,04x
Yield 2020 -
Capitalization 355 M 416 M 416 M
EV / Sales 2020 323x
EV / Sales 2021 118x
Nbr of Employees -
Free-Float 41,0%
Chart HYLORIS PHARMACEUTICALS SA
Duration : Period :
Hyloris Pharmaceuticals SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends HYLORIS PHARMACEUTICALS SA
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 13,75 €
Average target price 16,50 €
Spread / Average Target 20,0%
EPS Revisions
Managers and Directors
Stijn van Rompay Chief Executive Officer, CFO & Executive Director
Stefan Yee Chairman
Dietmar Aichhorn Chief Operating Officer
Marc Foidart Independent Director
Carolyn J. Myers Independent Director
Sector and Competitors
1st jan.Capi. (M$)
HYLORIS PHARMACEUTICALS SA44.74%416
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.20.05%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037